anbenitamab + albumin-bound docetaxel + carboplatin

KN026 + HB1801 + carboplatin is an investigational combination chemotherapy and immunotherapy regimen being evaluated for the treatment of HER2-positive breast cancer. The regimen consists of three active components: anbenitamab (KN026), a recombinant humanized bispecific monoclonal antibody targeting two non-overlapping extracellular domains of the HER2 receptor (ECD2 and ECD4); HB1801, a solvent-free, albumin-bound nanoparticle formulation of the taxane chemotherapy docetaxel; and carboplatin, a platinum-based chemotherapeutic agent. Anbenitamab provides targeted anti-HER2 activity by blocking downstream signaling, promoting receptor internalization, and inducing antibody-dependent cellular cytotoxicity (ADCC). HB1801 delivers docetaxel encapsulated in human serum albumin, which improves safety and tolerability by eliminating the need for solvent-based vehicles like polysorbate 80 and ethanol. Carboplatin acts as a DNA alkylating agent, causing DNA cross-linking and inducing apoptosis. This combination is being evaluated in Phase III clinical trials (such as the Neo-Healer trial) as a neoadjuvant treatment for patients with early or locally advanced HER2-positive breast cancer.